WO2021116820A1 - An improved process for the preparation of benoxaprofen - Google Patents

An improved process for the preparation of benoxaprofen Download PDF

Info

Publication number
WO2021116820A1
WO2021116820A1 PCT/IB2020/061304 IB2020061304W WO2021116820A1 WO 2021116820 A1 WO2021116820 A1 WO 2021116820A1 IB 2020061304 W IB2020061304 W IB 2020061304W WO 2021116820 A1 WO2021116820 A1 WO 2021116820A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
give
acid
benoxaprofen
sodium
Prior art date
Application number
PCT/IB2020/061304
Other languages
French (fr)
Inventor
Naganaboina VIJAYA KUMAR
Konduru RAJASHEKARA RAJU
Kurimisetty SIVA KUMAR
Nagari Madugu MAHESH
Neela Praveen Kumar
Meenakshisunderam Sivakumaran
Original Assignee
Aurobindo Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Limited filed Critical Aurobindo Pharma Limited
Publication of WO2021116820A1 publication Critical patent/WO2021116820A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals

Definitions

  • the present invention relates to an improved process for the preparation of Benoxaprofen having formula (I) and its intermediate thereof.
  • Benoxaprofen (I) is chemically known as 2-(4-chlorophenyl)-a-methyl-5- benzoxazoleacetic acid. Benoxaprofen (I) is a non-steroidal anti-inflammatory drug (NSAID).
  • NSAID non-steroidal anti-inflammatory drugs
  • Non-steroidal anti-inflammatory drugs are a class of medications that possess analgesic and anti-pyretic activities. They are used for reducing body pains, cold, fever and inflammation in a large variety of musculoskeletal disorders, menstrual cramps.
  • NSAIDS are perhaps most popular new group of medications in the market today. Generally, these drugs are used to treat all kinds of pain including rheumatoid arthritis, pain caused by autoimmune disease and physical trauma.
  • the US Patent RE ‘608 described a process for the preparation of Benoxaprofen of formula (I) comprising: a Sandmeyer reaction, by diazotization of 2-(4-aminophenyl)propanenitrile of formula (a) with sodium nitrite followed by acid hydrolysis to give 2-(4-hydroxyphenyl)propionitrile of formula (b), which further undergoes nitration with nitric acid in presence of acetic acid to give 2-(3- nitro-4-hydroxyphenyl)propionitrile of formula (c) followed by reduction with stannous chloride dihydrate or with 10% palladium carbon to give 2-(3-amino-4- hydroxyphenyl)propionitrile of formula (d).
  • ES 8302676 A1 of Ferrer International S.A described a process for the preparation of Benoxaprofen of formula (I), by acylation of compound of formula (k) with p-chlorobenzoyl chloride of formula (e) which is further heated to dehydration to give corresponding 2-phenyl benzoxazole (1) which further undergoes Grignard reaction to give Benoxaprofen (I).
  • the process is schematically represented in Scheme-Ill.
  • the disadvantage of the above said process is that it leads to the formation of a dimethyl impurity in methylation step which is difficult to eliminate in purification. Further, it is very difficult to remove unreacted intermediate (q) in the purification and also involves low temperature reaction (-78°C) in final stage.
  • the primary objective of the present invention is to provide an improved process for the preparation of Benoxaprofen of formula (I).
  • Another objective of the present invention is to provide a simple, cost effective & industrially viable process for the preparation of Benoxaprofen of formula (I) having good yield and purity.
  • the present invention provides an improved and cost effective process for the preparation of Benoxaprofen of formula (I). which comprises: i) Reaction of N-(5-acetyl-2-hydroxyphenyl)-4-chlorobenzamide of formula (VI): with a base and in the presence of a catalyst to give l-(2-(4-chlorophenyl)benzo[d] oxazol-5-yl)-ethanone of formula (V); ii) Reaction of compound of formula (V) with isopropyl chloroacetate in the presence of metal alkoxides to give epoxy ester intermediate of formula (IV); iii) Hydrolysis of compound of formula (IV) to give salt of epoxy acid compound of formula (III)
  • the present invention provides an improved process for the preparation of Benoxaprofen of formula (I); which comprises : i) reaction of N-(5-acetyl-2-hydroxyphenyl)-4-chlorobenzamide of formula (VI): with a base and in the presence of a catalyst to give l-(2-(4-chlorophenyl)benzo[d] oxazol-5-yl)-ethanone of formula (V); which may be optionally isolated or carried forward as such to the next step without isolation.
  • M is Na, Kor Li followed by acidification using inorganic acid to give an aldehyde compound of formula (II); iv) Oxidation of aldehyde compound of formula (II) using a suitable oxidising agent to give Benoxaprofen crude compound of formula (I) which is optionally purified to give pure Benoxaprofen.
  • the process for preparation of Benoxaprofen as described in the present invention is schematically represented as shown below.
  • the base used in the intramolecular cyclisation of compound of formula VI comprises, triethylamine, pyridine or DIPEA (N,N-Diisopropylethylamine).
  • the catalyst comprises, methane sulfonic acid, para toluene sulfonic acid or pyridinium para-toluene sulfonate.
  • the solvent comprises, aprotic solvents toluene, hexane, dichloromethane, acetone, tetrahydrofuran, dimethyl sulfoxide and dimethyl formamide or mixtures thereof.
  • the base used in the epoxidation step comprises, alkali alkoxides selected from sodium methoxide, sodium ethoxide, sodium isopropoxide, sodium tertiary butoxide, potassium methoxide, potassium i-butoxide or potassium tertiary butoxide.
  • the solvent comprises, polar aprotic solvents selected from tetrahydrofuran, dimethyl sulfoxide and dimethyl formamide or mixture thereof.
  • alkali metal hydroxide comprises sodium, potassium or lithium hydroxides or mixtures thereof, preferably sodium hydroxide.
  • Acidification of salt of acid is carried out in presence of mineral acids comprises hydrochloric acid, sulphuric acid or nitric acid.
  • Oxidation of aldehyde intermediate is carried out in the presence of oxidising agents comprises potassium permanganate, peroxy acids, hydrogen peroxide, sodium chlorite, oxone, Jones reagent or a mixture thereof to provide the desired acid compound.
  • Purification of crude Benoxaprofen is further carried out in solvents comprises water, methanol, ethanol, propanol, isopropanol, butanol ethylacetate, acetone, methyl ethyl ketone, methyl isobutyl ketone or mixture thereof.
  • Step-I N-(5-Acetyl-2-hydroxyphenyl)-4-chlorobenzamide of formula (VI) (185 g) was suspended in toluene (2000 ml) at 20-30°C. Triethylamine (74.16 g) was added to the reaction mixture. Methane sulfonic acid (104.2g) was added to the reaction mass at 20-45°C over a period of 55 to 65 min. The reaction was heated to 110-115°C with removal of water azeotropically. The reaction was monitored by HPLC, after completion of reaction, reaction mixture was concentrated under reduced pressure at 60-65°C. Isopropyl alcohol was added to the concentrated mass at 40-50°C.
  • reaction mixture was heated to 65-70°C with continuous stirring and cooled to 10-15°C, stirred at this temperature for 40 to 50 minutes. Filtered the product and washed with precooled isopropyl alcohol, dried the product under reduced pressure at 60-65°C to get title compound of formula V.
  • Step-II l-(2-(4-Chlorophenyl)benzo[d]oxazol-5-yl)ethanone compound of formula (V) (25. Og) was suspended in tetrahydrofuran (250.0 mL) under nitrogen atmosphere. Isopropyl chloroacetate (25. Og) was added to this mixture at 20-30°C and the reaction mass was cooled to 10-15°C. Sodium ethoxide solution (58.4g) was added over a period of 30 minutes and continued stirring at this temperature for 2 hours ⁇ 15 min. The reaction was monitored by HPLC, after completion of reaction, DM water (25 mL) was added to the reaction mass at 10-20°C. The reaction mass was proceeded to the next step without isolation of epoxy ester intermediate.
  • Step-III Sodium hydroxide (50% w/w, 7.35g) solution was added to the reaction mass obtained in step-II and stirred at 10-15°C. The reaction was monitored by HPLC. After completion of reaction, DM water (lOmL) was added to the reaction mass at 20-30°C. The reaction mass was concentrated under reduced pressure at 10-50°C till the reaction mass volume was reduced to ⁇ 75mL. The ⁇ reaction mass was cooled to 20-30°C and DM water was added (75mL). This reaction mass was proceeded to next step without isolation.
  • Step-IV The pH of the reaction mass obtained from step -III was adjusted to 4.0 - 4.2 with cone. Hydrochloric acid ( ⁇ 10mL) at 20-30°C. The reaction mass was heated to reflux (65- 75°C) and maintained at this temperature for completion of epoxy acid intermediate. The reaction was monitored by HPLC. After completion of epoxy acid intermediate, the reaction mass was cooled to 50-60°C and toluene (150mL) and DM water (125mL) were added at 50-60°C. It was allowed to stir at 50-60°C for 20-25 min. The organic layer was separated and washed with water, the organic layer was further concentrated under reduced pressure at 10-50°C till reaction mass volume was about ⁇ 130mL.
  • Step-V Acetonitrile (25mL) was charged into a solution of benzoxazole aldehyde solution obtained in previous stage at 20-30°C and cooled to 5-15°C. Hydrogen peroxide (12.5g) was added to the reaction mass at 5-15°C and later the pH was adjusted to 3.2 ⁇ 0.5 with aqueous sodium dihydrogen phosphate solution (lOOmL) at 5-15°C followed by addition of Potassium bromide (0.25g). 80% (w/w) Sodium chlorite solution ( ⁇ 95mL) was added to this reaction mixture at 5-15°C for a period of 1 hour ⁇ 5 min. The reaction mixture was stirred at 5-15°C until the completion of reaction which was monitored by HPLC.
  • Step- VI The crude Benoxaprofen compound (16g) was suspended in methyl isobutyl ketone (MIBK) (288mL) at 25-30°C. The reaction mass was then heated to 110-115°C. To this reaction mass carbon enoanticromos (0.8g) was added and continued to stir at this temperature for 15-20 min.
  • MIBK methyl isobutyl ketone
  • reaction mass was then passed through celite bed and washed with MIBK (32mL) at 110-115°C.
  • MIBK 32mL
  • the fdtrate was concentrated under reduced pressure at 50-60°C to obtain a reaction mass volume ⁇ 130mL, cooled the slurry mass to 20-25°C and stirred for lhour ⁇ 1 Omin.
  • the resulting product was filtered, washed and dried to get pure Benoxaprofen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to an improved process for the preparation of Benoxaprofen of formula (I) and its intermediate compounds of (II) & (IV) thereof.

Description

AN IMPROVED PROCESS FOR THE PREPARATION OF BENOXAPROFEN
FILED OF THE INVENTION
The present invention relates to an improved process for the preparation of Benoxaprofen having formula (I) and its intermediate thereof.
Figure imgf000002_0001
BACK GROUND OF THE INVENTION
Benoxaprofen (I) is chemically known as 2-(4-chlorophenyl)-a-methyl-5- benzoxazoleacetic acid. Benoxaprofen (I) is a non-steroidal anti-inflammatory drug (NSAID). Non-steroidal anti-inflammatory drugs are a class of medications that possess analgesic and anti-pyretic activities. They are used for reducing body pains, cold, fever and inflammation in a large variety of musculoskeletal disorders, menstrual cramps. NSAIDS are perhaps most popular new group of medications in the market today. Generally, these drugs are used to treat all kinds of pain including rheumatoid arthritis, pain caused by autoimmune disease and physical trauma.
The US Patent US RE 29,608 covered Benoxaprofen (I) as a product and process for the preparation thereof.
Figure imgf000002_0002
The US Patent RE ‘608 described a process for the preparation of Benoxaprofen of formula (I) comprising: a Sandmeyer reaction, by diazotization of 2-(4-aminophenyl)propanenitrile of formula (a) with sodium nitrite followed by acid hydrolysis to give 2-(4-hydroxyphenyl)propionitrile of formula (b), which further undergoes nitration with nitric acid in presence of acetic acid to give 2-(3- nitro-4-hydroxyphenyl)propionitrile of formula (c) followed by reduction with stannous chloride dihydrate or with 10% palladium carbon to give 2-(3-amino-4- hydroxyphenyl)propionitrile of formula (d). The obtained propionitrile reacts with p-chlorobenzoyl chloride of formula (e) in presence of pyridine to give p-chloro-2- (3-benzamido-4-hydroxyphenyl)propionitrile as an oil which was recrystallized in methanol to obtain p-chloro-2-(2-phenyl-5-benzoxazolyl)propionitrile of formula (f). Finally, hydrolysis with cone. HC1 gave Benoxaprofen of formula (I). The process is schematically represented in scheme-I:
H2N Sodium nitrite H Hydrochloric acid Nitric acid Acetic acid
Figure imgf000003_0001
CN Sulphuric acid
Figure imgf000003_0002
CN CN
Figure imgf000003_0003
(a) CH3 Sodium hydroxide Ether (b) CH3 (c) CH
SnCl2.2 H2O 10 % Pd-C Hydrochloric acid Ethanol
Or
Figure imgf000003_0004
Figure imgf000003_0005
Scheme-I
ES 8203863 A1 of Medichem, described a process for the preparation of Benoxaprofen of formula (I), by diazotisation of formula (a) to give formula (b) which further undergoes nitration to give nitro compound of formula (c), the obtained nitro compound was reduced to give amine compound of formula (d). The obtained formula (d) was further condensed with compound of formula (g) to give formula (f). Finally, hydrolysis of formula (f) gives Benoxaprofen of formula (I). The process is schematically represented in scheme-II:
Figure imgf000004_0001
Scheme-II
The processes described in the above literature references are having the following disadvantages: i) starting material (a) is not available easily; and ii) involves the use of most hazardous reagents like cyanides.
ES 8302676 A1 of Ferrer International S.A described a process for the preparation of Benoxaprofen of formula (I), by acylation of compound of formula (k) with p-chlorobenzoyl chloride of formula (e) which is further heated to dehydration to give corresponding 2-phenyl benzoxazole (1) which further undergoes Grignard reaction to give Benoxaprofen (I). The process is schematically represented in Scheme-Ill.
Figure imgf000005_0002
Scheme-Ill
The process described in above literature reference involves highly exothermic Grignard reaction and therefore becomes very critical during large scale production.
Synthetic communications, (1985), 15(12), Pg. No. 1075-1080 reported a process for the preparation of Benoxaprofen of formula (I) which is represented in scheme-IV :
Figure imgf000005_0001
Scheme-IV Where in R’ is CH3.
The disadvantage of the above said process is that it leads to the formation of a dimethyl impurity in methylation step which is difficult to eliminate in purification. Further, it is very difficult to remove unreacted intermediate (q) in the purification and also involves low temperature reaction (-78°C) in final stage.
In view of the preparation methods available for Benoxaprofen, there is a need for simple, cost effective, environmental friendly, commercially scalable, feasible process for the preparation of highly pure Benoxaprofen (I).
OBJECTIVE OF THE INVENTION
The primary objective of the present invention is to provide an improved process for the preparation of Benoxaprofen of formula (I). Another objective of the present invention is to provide a simple, cost effective & industrially viable process for the preparation of Benoxaprofen of formula (I) having good yield and purity.
SUMMARY OF THE INVENTION In one embodiment, the present invention provides an improved and cost effective process for the preparation of Benoxaprofen of formula (I).
Figure imgf000006_0001
which comprises: i) Reaction of N-(5-acetyl-2-hydroxyphenyl)-4-chlorobenzamide of formula (VI):
Figure imgf000007_0001
with a base and in the presence of a catalyst to give l-(2-(4-chlorophenyl)benzo[d] oxazol-5-yl)-ethanone of formula (V);
Figure imgf000007_0002
ii) Reaction of compound of formula (V) with isopropyl chloroacetate in the presence of metal alkoxides to give epoxy ester intermediate of formula (IV);
Figure imgf000007_0003
iii) Hydrolysis of compound of formula (IV) to give salt of epoxy acid compound of formula (III)
Figure imgf000008_0001
M is Na, Kor Li followed by acidification to give aldehyde compound of formula (II);
Figure imgf000008_0002
iv) Oxidation of aldehyde compound of formula (II) to give Benoxaprofen of formula (I).
DETAILED DESCRIPTION OF THE INVENTION
In one embodiment, the present invention provides an improved process for the preparation of Benoxaprofen of formula (I);
Figure imgf000008_0003
which comprises : i) reaction of N-(5-acetyl-2-hydroxyphenyl)-4-chlorobenzamide of formula (VI):
Figure imgf000009_0001
with a base and in the presence of a catalyst to give l-(2-(4-chlorophenyl)benzo[d] oxazol-5-yl)-ethanone of formula (V);
Figure imgf000009_0002
which may be optionally isolated or carried forward as such to the next step without isolation. ii) Reaction of compound of formula (V) with isopropyl chloroacetate in the presence of metal alkoxide to give epoxy ester intermediate of formula (IV);
Figure imgf000009_0003
which may be optionally isolated or carried forward as such to the next step without isolation. iii) Hydrolysis of compound of formula (IV) using alkali hydroxide to give corresponding salt of epoxy acid compound of formula (III);
Figure imgf000010_0001
M is Na, Kor Li followed by acidification using inorganic acid to give an aldehyde compound of formula (II);
Figure imgf000010_0002
iv) Oxidation of aldehyde compound of formula (II) using a suitable oxidising agent to give Benoxaprofen crude compound of formula (I) which is optionally purified to give pure Benoxaprofen. The process for preparation of Benoxaprofen as described in the present invention is schematically represented as shown below.
Figure imgf000011_0001
The base used in the intramolecular cyclisation of compound of formula VI comprises, triethylamine, pyridine or DIPEA (N,N-Diisopropylethylamine). The catalyst comprises, methane sulfonic acid, para toluene sulfonic acid or pyridinium para-toluene sulfonate. The solvent comprises, aprotic solvents toluene, hexane, dichloromethane, acetone, tetrahydrofuran, dimethyl sulfoxide and dimethyl formamide or mixtures thereof. The base used in the epoxidation step comprises, alkali alkoxides selected from sodium methoxide, sodium ethoxide, sodium isopropoxide, sodium tertiary butoxide, potassium methoxide, potassium i-butoxide or potassium tertiary butoxide. The solvent comprises, polar aprotic solvents selected from tetrahydrofuran, dimethyl sulfoxide and dimethyl formamide or mixture thereof.
Hydrolysis is carried out in presence of alkali metal hydroxide comprises sodium, potassium or lithium hydroxides or mixtures thereof, preferably sodium hydroxide.
Acidification of salt of acid is carried out in presence of mineral acids comprises hydrochloric acid, sulphuric acid or nitric acid.
Oxidation of aldehyde intermediate is carried out in the presence of oxidising agents comprises potassium permanganate, peroxy acids, hydrogen peroxide, sodium chlorite, oxone, Jones reagent or a mixture thereof to provide the desired acid compound.
Purification of crude Benoxaprofen is further carried out in solvents comprises water, methanol, ethanol, propanol, isopropanol, butanol ethylacetate, acetone, methyl ethyl ketone, methyl isobutyl ketone or mixture thereof.
The invention is illustrated with the following example, which is provided by way of illustration only and should not be construed to limit the scope of invention in any manner whatsoever.
EXAMPLE:
PREPARATION OF BENOXAPROFEN:
Step-I: N-(5-Acetyl-2-hydroxyphenyl)-4-chlorobenzamide of formula (VI) (185 g) was suspended in toluene (2000 ml) at 20-30°C. Triethylamine (74.16 g) was added to the reaction mixture. Methane sulfonic acid (104.2g) was added to the reaction mass at 20-45°C over a period of 55 to 65 min. The reaction was heated to 110-115°C with removal of water azeotropically. The reaction was monitored by HPLC, after completion of reaction, reaction mixture was concentrated under reduced pressure at 60-65°C. Isopropyl alcohol was added to the concentrated mass at 40-50°C. The reaction mixture was heated to 65-70°C with continuous stirring and cooled to 10-15°C, stirred at this temperature for 40 to 50 minutes. Filtered the product and washed with precooled isopropyl alcohol, dried the product under reduced pressure at 60-65°C to get title compound of formula V.
Average Yield: 157.5 grams.
HPLC purity: 98.5%.
Figure imgf000013_0001
Step-II: l-(2-(4-Chlorophenyl)benzo[d]oxazol-5-yl)ethanone compound of formula (V) (25. Og) was suspended in tetrahydrofuran (250.0 mL) under nitrogen atmosphere. Isopropyl chloroacetate (25. Og) was added to this mixture at 20-30°C and the reaction mass was cooled to 10-15°C. Sodium ethoxide solution (58.4g) was added over a period of 30 minutes and continued stirring at this temperature for 2 hours ±15 min. The reaction was monitored by HPLC, after completion of reaction, DM water (25 mL) was added to the reaction mass at 10-20°C. The reaction mass was proceeded to the next step without isolation of epoxy ester intermediate.
Figure imgf000014_0001
Step-III: Sodium hydroxide (50% w/w, 7.35g) solution was added to the reaction mass obtained in step-II and stirred at 10-15°C. The reaction was monitored by HPLC. After completion of reaction, DM water (lOmL) was added to the reaction mass at 20-30°C. The reaction mass was concentrated under reduced pressure at 10-50°C till the reaction mass volume was reduced to ~ 75mL. The ± reaction mass was cooled to 20-30°C and DM water was added (75mL). This reaction mass was proceeded to next step without isolation.
Figure imgf000014_0002
Step-IV: The pH of the reaction mass obtained from step -III was adjusted to 4.0 - 4.2 with cone. Hydrochloric acid (~10mL) at 20-30°C. The reaction mass was heated to reflux (65- 75°C) and maintained at this temperature for completion of epoxy acid intermediate. The reaction was monitored by HPLC. After completion of epoxy acid intermediate, the reaction mass was cooled to 50-60°C and toluene (150mL) and DM water (125mL) were added at 50-60°C. It was allowed to stir at 50-60°C for 20-25 min. The organic layer was separated and washed with water, the organic layer was further concentrated under reduced pressure at 10-50°C till reaction mass volume was about ~130mL.
Figure imgf000015_0001
Step-V : Acetonitrile (25mL) was charged into a solution of benzoxazole aldehyde solution obtained in previous stage at 20-30°C and cooled to 5-15°C. Hydrogen peroxide (12.5g) was added to the reaction mass at 5-15°C and later the pH was adjusted to 3.2 ± 0.5 with aqueous sodium dihydrogen phosphate solution (lOOmL) at 5-15°C followed by addition of Potassium bromide (0.25g). 80% (w/w) Sodium chlorite solution (~95mL) was added to this reaction mixture at 5-15°C for a period of 1 hour ± 5 min. The reaction mixture was stirred at 5-15°C until the completion of reaction which was monitored by HPLC.
After completion of reaction, 20% aqueous sodium sulphite solution (~55mL) was added to the reaction mass followed by dilution with ethyl acetate (250mL) and DM water (75mL) at 5-15°C. The reaction mass was warmed to 40-
50°C stirred for 10-15 min. The organic layer was allowed to settle and separated. The aqueous layer was further extracted with ethyl acetate (75mL) at 40-50°C. DM water (5mL) was added to the combined organic layer and adjusted the pH to 12.3±0.2 with aqueous sodium hydroxide solution (60mL) at 40-50°C. The reaction mixture was stirred at 40-50°C for 10-15 min, the layers were allowed to settle and separated the aqueous layer. 250mL of ethyl acetate was added to the aqueous layer and adjusted the pH the reaction mass to 3.4±0.2 with cone. Hydrochloric acid (lOmL) at 20-30°C. The organic layer was separated and further extracted the aqueous layer with ethyl acetate (25mL) at 20-30°C. The combined organic layers were concentrated under reduced pressure which was further slurried in ethyl acetate (250mL). It was then cooled, filtered and washed with ethyl acetate to give Benoxaprofen crude (16.8g).
Figure imgf000016_0001
Step- VI: The crude Benoxaprofen compound (16g) was suspended in methyl isobutyl ketone (MIBK) (288mL) at 25-30°C. The reaction mass was then heated to 110-115°C. To this reaction mass carbon enoanticromos (0.8g) was added and continued to stir at this temperature for 15-20 min. the reaction mass was then passed through celite bed and washed with MIBK (32mL) at 110-115°C. The fdtrate was concentrated under reduced pressure at 50-60°C to obtain a reaction mass volume ~ 130mL, cooled the slurry mass to 20-25°C and stirred for lhour ± 1 Omin. The resulting product was filtered, washed and dried to get pure Benoxaprofen
Average Yield: 14.4 grams. HPLC purity: 99.94%.
Ή NMR: 1.45 (d, 3H), 3.89 (q, 1H), 7.36-8.20 (m, 7H, Ar-H), 12.37 (S, 1H)

Claims

We Claim:
1. A process for the preparation of Benoxaprofen of formula (I),
Figure imgf000017_0001
which comprises the steps of: i) Reaction of N-(5-acetyl-2-hydroxyphenyl)-4-chlorobenzamide of formula (VI);
Figure imgf000017_0002
with a base and in the presence of a catalyst to give l-(2-(4-chlorophenyl)benzo[d] oxazol -5-yl)ethanone of formula (V);
Figure imgf000017_0003
ii) Reaction of compound of formula (V) with isopropyl chloroacetate in the presence of metal alkoxides to give epoxy ester intermediate of formula (IV);
Figure imgf000018_0001
iii) Hydrolysis of compound of formula (IV) to give salt of epoxy acid compound of formula (III);
Figure imgf000018_0002
M is Na, Kor Li followed by acidification to give aldehyde compound of formula (II);
Figure imgf000018_0003
iv) Oxidation of aldehyde compound of formula (II) to give Benoxaprofen of formula (I).
2. The process as claimed in claim 1, wherein the base used in step (i) comprises organic base selected from triethylamine, pyridine or diisopropylethyl amine. 3 The process as claimed in claim 1, wherein the catalyst used in step (i) comprises, methanesulfonic acid, para toluene sulfonic acid or pyridinium para- toluene sulfonate.
4 The process as claimed in claim 1, wherein the solvent used in step (i) comprises aprotic solvents selected from toluene, hexane, dichloromethane, acetone, tetrahydrof iran, dimethyl sulfoxide and dimethyl formamide or mixture thereof.
5 The process as claimed in claim 1, wherein the metal alkoxides used in step (ii), comprises sodium methoxide, sodium ethoxide, sodium isopropoxide, sodium tertiary butoxide, potassium methoxide, potassium i-butoxide or potassium tertiary butoxide.
6 The process as claimed in claim 1, wherein the solvent used in step (ii), comprises polar aprotic solvents selected from tetrahydro furan, dimethyl sulfoxide and dimethyl formamide or mixture thereof.
7 The process as claimed in claim 1, wherein the base used in step (iii) comprises alkali metal hydroxide selected from sodium hydroxide, potassium hydroxide or lithium hydroxide or mixtures thereof.
8 The process as claimed in claim 1, wherein acidification of salt is carried out in presence of an acid comprises mineral acids selected from, hydrochloric acid, sulphuric acid and nitric acid. 9 The process as claimed in claim 1, wherein the oxidising agents used in step (iv), comprises, potassium permanganate, peroxy acids, hydrogen peroxide, sodium chlorite, oxone, Jones reagent or mixtures thereof.
Figure imgf000019_0001
PCT/IB2020/061304 2019-12-10 2020-12-01 An improved process for the preparation of benoxaprofen WO2021116820A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941050906 2019-12-10
IN201941050906 2019-12-10

Publications (1)

Publication Number Publication Date
WO2021116820A1 true WO2021116820A1 (en) 2021-06-17

Family

ID=76329926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/061304 WO2021116820A1 (en) 2019-12-10 2020-12-01 An improved process for the preparation of benoxaprofen

Country Status (1)

Country Link
WO (1) WO2021116820A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000276B1 (en) * 1977-06-28 1982-09-01 Lilly Industries Limited A novel crystalline form of benoxaprofen, methods of preparation thereof and pharmaceutical formulations containing said novel form
WO2004046122A2 (en) * 2002-11-16 2004-06-03 Oxford Glycosciences (Uk) Ltd Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors
EP1688413A1 (en) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000276B1 (en) * 1977-06-28 1982-09-01 Lilly Industries Limited A novel crystalline form of benoxaprofen, methods of preparation thereof and pharmaceutical formulations containing said novel form
WO2004046122A2 (en) * 2002-11-16 2004-06-03 Oxford Glycosciences (Uk) Ltd Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors
EP1688413A1 (en) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases

Similar Documents

Publication Publication Date Title
US7459580B2 (en) Process for trans-4-amino-1-cyclohexanecarboxilic acid derivatives
KR101532570B1 (en) Compounds useful in the synthesis of benzamide compounds
US20200385355A1 (en) Method for synthesis of roxadustat and intermediate compounds thereof
JP3393891B2 (en) Method for producing imidazoles
JP2018507871A (en) Process for producing 3-chloro-2-vinylphenylsulfonates
US20240132459A1 (en) Process and intermediates for the preparation of certain nematicidal sulfonamides
WO2021116820A1 (en) An improved process for the preparation of benoxaprofen
US8598387B2 (en) Process for the preparation of atovaquone
US7109353B2 (en) Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCl
TWI438180B (en) New process for the synthesis of agomelatine
KR20040010779A (en) A new compound for the treatment of impotence
CN107200729B (en) Preparation method of 4- (2-methoxyphenyl) -5- (2-pyridyl) -3-aminoisoxazole
WO2010149360A1 (en) Process for the preparation of benzimidazoles
CN114394908B (en) Method for preparing 2-hydroxy-3-aminoacetophenone
CA2163601C (en) 2-aminobenzenesulfonic acid and 2-aminobenzenesulfonyle chloride derivatives
WO2018028665A1 (en) Method for preparing intermediate of 6-arylaminopyridonecarboxamide compound as mek inhibitor
JP2003212861A (en) Method for producing pyrimidinyl alcohol derivative and synthetic intermediate thereof
JP6256469B2 (en) Process for the preparation of spiro [2.5] octane-5,7-dione
CN110423224B (en) Synthesis method of 2-aminopyrimidine type antiplatelet compound
EP3091000A1 (en) Synthetic process of carprofen
US20050209332A1 (en) Gabapentin analogues and process thereof
JPH06247918A (en) Preparation of phenylbenzamide derivative
JPH051023A (en) Production of alkanesulfonanilide derivative
US10710972B2 (en) Method for preparing substituted 2,3-dihydro-1-benzofuran derivatives
Conway et al. An Efficient One-Pot Synthesis of Hippuric Acid Ethyl Ester Derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20898772

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20898772

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 20898772

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 29/03/2023)

122 Ep: pct application non-entry in european phase

Ref document number: 20898772

Country of ref document: EP

Kind code of ref document: A1